Indian pharmaceutical market has registered a sales growth of 9.6 per cent at Rs. 8,989 crore for the month of March 2017, which is much higher than March 2016 growth of 8 per cent. The market growth was at 7.1 per cent in February 2017. Major segments like cardiac, anti-diabetic and derma have grown by double digit.

According to AIOCD AWACS report the first quarter ended March 2017 saw a sales volume growth of 4 per cent & price growth at 1.4 per cent which has been consistently falling down.

FDC related market showed a degrowth of -24.9 per cent while the non FDC market is growing at 10.5 per cent. Volumes are pulling down the growth for the FDCs. Indian companies showed a degrowth of -21.2 per cent while MNC showed a degrowth of -33.4 per cent in the FDC segment in the March 2017.

Amongst the Top 10 Corporates, Zydus has the highest growth at 12.1 per cent followed by Alkem at 11.2, Sun at 11.1 per cent. 28 corporate have crossed the growth of IPM for the month of Mar-17 amongst top 50. Amongst the top 50 corporate USV has the highest growth of 30.6 per cent followed by Bharat Serums at 29.3 per cent and Himalaya at 28.1 per cent. 27 corporate showed growths more than 10 per cent amongst the top 50.

Amongst the 11-20 ranked corporate, USV has the highest growth at 30.6 per cent followed by Micro 24 per cent & Emcure at 16.5 per cent. Amongst the 21-30 ranked corporate, Himalaya showed the highest growth at 28.1 per cent followed by Eris at 17.6 per cent & Ipca at 13.1 per cent.

Abbott HC grew at 2.4 per cent whereas Abbott India grew at 11.1 per cent for the month of March-17. Zuventus grows at 13.8 per cent, Emcure at 18.3 per cent Novo Nordisk grows at 21.7 per cent. Sun portfolio grew by 14.9 per cent whereas Ranbaxy portfolio grew at 5.9 per cent.

Indian companies dominated the IPM and drive growth. Six out of top 10 MNCs are showing single digit growth with GSK in negative. Indian companies grew by 10.3 per cent for the month while the MNC grew by 7.1 per cent. Amongst the top 50 in MNCs, Boehringer Ingelheim grew at 22.6 per cent followed by AstraZeneca growing at 24.2 per cent and Sanofi which grew at 11.5 per cent. Under the Non-NLEM category Indian companies grew at12.6 per cent whereas MNCs grew at 9.6 per cent

From therapy perspective 9 therapies have outgrown the IPM growth for the month of March 2017. Respiratory market grew at 7.8 per cent, gastro intestinal market grew at 9.3 per cent, pain & analgesics market grew at 8.5 per cent and anti infectives degrowth has been stemmed as it showed a small growth of 0.8 per cent. Anti-diabetic market grows at 23.1 per cent & cardiac at 11.3 per cent, neuro/CNS at 5.3 per cent in chronic business.  Anti-malarials degrew at -13.7 per cent & VMS market grew at 6.8 per cent. Derma surged at 16.6 per cent for the month of March 2017.

Total 273 brands and 532 SKUs were launched in March 2017. Instgra, azmarda, sabi glo Ml, paciliaqualip, cisblok, magnamontL remained as first 5 top brands. Azilsartan is launched by more 4 companies.